Roche’s Phase III MAJESTY Study Shows Gazyva®/Gazyvaro® Achieves Superior Remission in Primary Membranous Nephropathy
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that its phase III MAJESTY study met its primary endpoint in adults with primary membranous nephropathy (PMN), demonstrating statistically significant and clinically meaningful results with Gazyva®/Gazyvaro® (obinutuzumab). At 104 weeks, significantly more patients treated with Gazyva/Gazyvaro achieved complete remission compared with those receiving tacrolimus. The safety profile was…
